Showing 651-660 of 10234 results for "".
Treating Psoriasis with FDA-Approved Medications in 2020
https://practicaldermatology.com/topics/psoriasis/treating-psoriasis-with-fda-approved-medications-in-2020/23212/A reference for all of the FDA-approved medications separated into topical treatments and systemic treatments.The Future Is Now: Technology for Skincare
https://practicaldermatology.com/topics/practice-management/the-future-is-now-technology-for-skincare/20814/AI and AR are changing the way skin care is prescribed.Pearls for Management of Pediatric Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/pearls-pediatric-management-atopic-dermatitis/27122/At the recently held 2024 American Academy of Dermatology (AAD) Innovation Academy dermatologist Lisa Swanson, MD, FAAD, presented new insights into pediatric atopic dermatitis (AD), emphasizing its wide-ranging impact on children's health, including increased risks of food allergies, infections, anAAD Wrap: What To Know from Dermatology’s Biggest Meeting
https://practicaldermatology.com/issues/april-2025/aad-wrap-what-to-know-from-dermatologys-biggest-meeting/35623/The 2025 American Academy of Dermatology (AAD) Annual Meeting brought together the dermatology community this past March to exchange groundbreaking research, innovative treatments, and technological advancements. For 4 days in Orlando, the meeting served as the hub of the dermatology profession, delThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeVtama Approved for AD in Adults and Children
https://practicaldermatology.com/series/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.Hidradenitis Suppurativa: A Patient’s Perspective
https://practicaldermatology.com/topics/rare-disease/hidradenitis-suppurativa-a-patients-perspective/27171/Adam Friedman, MD, FAAD, presents a first-hand account of a patient living with hidradenitis suppurativa (HS).PA Perspectives - Building a Schedule
https://practicaldermatology.com/series/pa-perspectives/pa-perspectives-building-schedule/24488/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, provides insights on what a PA should be providing to an MD and their office staff. He also discusses realistic expectations for a new PA regarding scheduling, and givDermWire TV: Maui Derm Highlights, Plus New and Emerging Treatments for HS and Acne
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-maui-derm-highlights-plus-new-and-emerging-treatments-for-hs-and-acne/20258/In this episode of DermWire TV, we recap the biggest news from Maui Derm 2024, including safety and efficacy studies on bimekizumab, deucravacitinib, and upadacitinib. Also from Maui Derm, Raj Chovatiya, MD, PhD, highlights new therapies to treat hidradenitis suppurativa and Julie Harper, MD, highliAngioleiomyoma in a Rare Location
https://practicaldermatology.com/topics/other-dermatology/angioleiomyoma-in-a-rare-location/24012/A minimally invasive treatment is used to treat a tumor in a cosmetically sensitive area.